The 2nd Jinling International Conference on Biochemical Analysis
Sponsored by Pharmaceutical Phase The 2nd Jinling International Biochemical Analysis Conference & Exhibition is held at4month18The event successfully concluded at Nanjing Zijin International Hotel on the 1st.50Industry experts from top-tier international and domestic sectors share their experiences, bringing together experts, scholars, industry practitioners, and researchers from all over the country.500More than a dozen people gathered together to discuss the cutting-edge technologies, innovation trends, and development opportunities in the pharmaceutical field.
The conference features multiple thematic forums, focusing on research on the quality of chemical bulk drugs, preparation quality, proteins,ADCIn-depth discussions were held on topics such as pharmaceutical substance control analysis, peptide drug quality research, nucleic acid drug quality research, and the control and analysis of cell gene therapy pharmaceutical substances, providing a rich academic exchange platform for participants.
Frost & SullivanFrost & SullivanZhang Chenyang, Senior Consulting Manager of the Life Sciences Business Unit at Frost & Sullivan (referred to as 'Frost & Sullivan'), was invited to attend the forum and participate in the special topic forum on 'Analysis and Quality Control of Cell and Gene Therapy Drugs', sharing the current market situation and development trends of gene drugs.
Senior Consulting Manager, Life Sciences Business Unit, Frost & Sullivan Greater China Zhang Chenyang
Zhang Chenyang pointed out that in recent years, the launch of gene drugs has accelerated, as of2024year2months, globally, have already13A gene therapy has been approved for marketing.2022year-2024year2month7The drug has been approved for marketing. The delivery systems for the approved products include viruses and plasmids. Among them,AAVCarriers are the most widely used due to their low immunogenicity, different tissue affinities among various subtypes, and relatively mature production processes.62%The gene therapy market, which has been listed, covers areas such as the blood system, metabolism, circulatory system, neuromusculoskeletal system, and oncology. From the perspective of the capital market,2023In the global primary market for gene drugs, several financing events have occurred. Capital continues to favor the gene drug sector, while transactions in the global and Chinese gene drug markets/Cooperation events are frequent, and the competition continues to heat up.
Source: Analysis by Frost & Sullivan
Zhang Chenyang stated that the research, development, and production of gene drugs pose significant high-tech barriers, mainly reflected in aspects such as delivery system safety, gene editing safety, gene expression regulation, precise targeting of lesions, large-scale production, and product quality control. In the future, with the continuous emergence and advancement of new technologies, the research, development, and production of gene drugs will embrace broader development space. At the same time, its application fields will continue to expand. With diversified payment models and reduced treatment costs, more patients will benefit.
More exciting moments from the event arena
About Frost & Sullivan's Life Sciences Practice
The Life Sciences Practice of Frost & Sullivan has professional analytical capabilities and extensive project experience in the field of life sciences. Leveraging Frost & Sullivan's global think tank resources and cross-industry business development platform in Greater China, the Life Sciences Practice has unique core advantages in investment and financing services for the life science industry. The Life Sciences Practice has a wide range of corporate clients in China and in the past20In the year, a vast customer network was established, accumulating extensive project experience in various subfields of life sciences.
Project types include Knowledge Center projects (in-depth content and promotional activities).Pre-IPO financingprojectDCF modelValuation, Business Plan Services),IPO listingWe provide listed projects (industry consulting, clinical audits, fundraising and investment writing), market research, market value management, and strategic consulting. We also cooperate with well-known domestic and international information platforms and investment and financing institutions to offer one-stop solutions for enterprises in specialized sub-sectors such as pharmaceuticals and medical devices. Our services have received wide attention from investors.
